CN101389656A - 抗骨膜素的抗体和含有该抗体的用于预防或治疗骨膜素相关疾病的药物组合物 - Google Patents

抗骨膜素的抗体和含有该抗体的用于预防或治疗骨膜素相关疾病的药物组合物 Download PDF

Info

Publication number
CN101389656A
CN101389656A CNA2006800533635A CN200680053363A CN101389656A CN 101389656 A CN101389656 A CN 101389656A CN A2006800533635 A CNA2006800533635 A CN A2006800533635A CN 200680053363 A CN200680053363 A CN 200680053363A CN 101389656 A CN101389656 A CN 101389656A
Authority
CN
China
Prior art keywords
antibody
record
periosteum
sequence number
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800533635A
Other languages
English (en)
Chinese (zh)
Inventor
谷山义明
森下龙一
葛城鸣门
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka University NUC
Original Assignee
Osaka University NUC
Asubio Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38228283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101389656(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Osaka University NUC, Asubio Pharma Co Ltd filed Critical Osaka University NUC
Publication of CN101389656A publication Critical patent/CN101389656A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
CNA2006800533635A 2005-12-28 2006-12-28 抗骨膜素的抗体和含有该抗体的用于预防或治疗骨膜素相关疾病的药物组合物 Pending CN101389656A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP380009/2005 2005-12-28
JP2005380009 2005-12-28

Publications (1)

Publication Number Publication Date
CN101389656A true CN101389656A (zh) 2009-03-18

Family

ID=38228283

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800533635A Pending CN101389656A (zh) 2005-12-28 2006-12-28 抗骨膜素的抗体和含有该抗体的用于预防或治疗骨膜素相关疾病的药物组合物

Country Status (9)

Country Link
EP (1) EP1978034B2 (fr)
JP (1) JP5019464B2 (fr)
KR (1) KR101363695B1 (fr)
CN (1) CN101389656A (fr)
AU (1) AU2006334029B2 (fr)
BR (1) BRPI0620747A2 (fr)
CA (1) CA2635849C (fr)
RU (1) RU2008130898A (fr)
WO (1) WO2007077934A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103688171A (zh) * 2010-12-16 2014-03-26 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗
WO2023036305A1 (fr) * 2021-09-13 2023-03-16 沈阳眼产业技术研究院有限公司 Anticorps monoclonal humanisé anti-périostine, procédé de préparation s'y rapportant et son utilisation

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017119B2 (en) 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
KR101560843B1 (ko) * 2007-06-27 2015-10-15 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
JP5717178B2 (ja) 2008-06-05 2015-05-13 国立大学法人佐賀大学 特発性間質性肺炎の検出方法
EP2399131B1 (fr) * 2009-02-20 2014-08-27 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Methode de diagnose des troubles vasculaire lies a l'age
SG10201408247SA (en) * 2009-02-24 2015-02-27 Esbatech Alcon Biomed Res Unit Methods for identifying immunobinders of cell-surface antigens
JP5555940B2 (ja) * 2010-04-14 2014-07-23 国立大学法人佐賀大学 増殖糖尿病網膜症の検出方法および予防・治療剤のスクリーニング方法
JP6183809B2 (ja) 2011-09-06 2017-08-23 株式会社シノテスト ペリオスチンの特定領域に結合する抗体及びこれを用いたペリオスチンの測定方法
WO2013038696A1 (fr) 2011-09-15 2013-03-21 国立大学法人名古屋大学 Marqueur moléculaire pour l'identification précoce de patients souffrant de mésothéliome pleural et procédé d'analyse d'expression associé
FR2992221A1 (fr) * 2012-06-22 2013-12-27 Centre Nat Rech Scient Modification des effets immunomodulateurs des cellules
WO2014013005A1 (fr) 2012-07-18 2014-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de prévention et de traitement de la maladie rénale chronique (mrc).
JP6218088B2 (ja) * 2013-03-08 2017-11-01 国立大学法人大阪大学 ペリオスチンのＥｘｏｎ−２１部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物
WO2015120171A1 (fr) * 2014-02-07 2015-08-13 Medimmune, Llc Nouvelle analyse permettant de détecter la périostine humaine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
EP0754225A4 (fr) 1993-04-26 2001-01-31 Genpharm Int Animaux transgeniques capables de produire des anticorps heterologues
ATE475432T1 (de) 2000-09-08 2010-08-15 Daiichi Sankyo Co Ltd Arzneimittel für herzversagen
CN102605062A (zh) * 2003-05-29 2012-07-25 千年药品公司 用于鉴定、评估、预防和治疗乳腺癌的组合物、试剂盒及方法
WO2005019471A2 (fr) * 2003-08-13 2005-03-03 Temple University Of The Commonwealth System Of Higher Education Facteur de type periostine, compositions et procedes de production et d'utilisation de ce facteur

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103688171A (zh) * 2010-12-16 2014-03-26 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗
CN105169390A (zh) * 2010-12-16 2015-12-23 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗
CN112168962A (zh) * 2010-12-16 2021-01-05 弗·哈夫曼-拉罗切有限公司 与th2抑制相关的诊断和治疗
WO2023036305A1 (fr) * 2021-09-13 2023-03-16 沈阳眼产业技术研究院有限公司 Anticorps monoclonal humanisé anti-périostine, procédé de préparation s'y rapportant et son utilisation

Also Published As

Publication number Publication date
EP1978034A1 (fr) 2008-10-08
KR20080099248A (ko) 2008-11-12
EP1978034A4 (fr) 2010-09-01
JP5019464B2 (ja) 2012-09-05
JPWO2007077934A1 (ja) 2009-06-11
BRPI0620747A2 (pt) 2011-11-22
AU2006334029A1 (en) 2007-07-12
CA2635849A1 (fr) 2007-07-12
KR101363695B1 (ko) 2014-02-14
WO2007077934A1 (fr) 2007-07-12
AU2006334029B2 (en) 2013-01-31
RU2008130898A (ru) 2010-02-10
CA2635849C (fr) 2017-05-09
EP1978034B2 (fr) 2018-05-16
EP1978034B1 (fr) 2014-09-17

Similar Documents

Publication Publication Date Title
CN101389656A (zh) 抗骨膜素的抗体和含有该抗体的用于预防或治疗骨膜素相关疾病的药物组合物
KR101429783B1 (ko) 항 인간 α９ 인테그린 항체와 그 용도
CN101103044B (zh) 抗α9整联蛋白抗体及其用途
EP2168599B1 (fr) Remède anticancéreux contenant un anticorps dirigé contre un peptide codé par l'exon-17 de la périostine
US8372957B2 (en) Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
CN107108738A (zh) 抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
US20060178503A1 (en) Antibody to an integrin heterodimer and/or a subunit thereof
JP2007523092A (ja) 新脈管形成阻害のための方法および組成物
US20190106484A1 (en) Antibody against peptide encoded by exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same
CN102675461A (zh) 针对可溶型lox-1的单克隆抗体
JP2008500004A (ja) ＣＤ４４ｖＲＡに対する抗体およびその使用方法
JP4469180B2 (ja) テネイシンｗ組成物およびその使用
CN103201291B (zh) 抗单链iv型胶原多肽抗体和包含其的用于诊断、预防或治疗肿瘤的药物或药剂
MX2008008584A (es) Anticuerpo contra periostina, y una composicion farmaceutica que lo comprende para prevenir o tratar una enfermedad en donde esta involucrada periostina.
Ayalon The structure and regulation of endothelial junctions

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SANKYO CO.

Free format text: FORMER OWNER: ASUBIO PHARMA CO., LTD.

Effective date: 20100907

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20100907

Address after: Tokyo, Japan

Applicant after: Sankyo Co.

Co-applicant after: National University Corporation Osaka University

Address before: Tokyo, Japan

Applicant before: Asubio Pharma Co., Ltd.

Co-applicant before: National University Corporation Osaka University

ASS Succession or assignment of patent right

Free format text: FORMER OWNER: UNIV OSAKA

Effective date: 20130402

Owner name: UNIV OSAKA

Free format text: FORMER OWNER: SANKYO CO.

Effective date: 20130402

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130402

Address after: Osaka Japan

Applicant after: National University Corporation Osaka University

Address before: Tokyo, Japan

Applicant before: Sankyo Co.

Applicant before: National University Corporation Osaka University

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20090318